Gleevec receives US approval as first treatment to ...


by MultiVu

  • About
  • Export
  • Add to
Gleevec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tumors Novartis announced today that Gleevec (imatinib mesylate) tablets* has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Gleevec is now the only post-surgery treatment indicated to delay the return of this highly aggressive cancer, filling a major need for GIST patients. The filing received FDA priority review status in August of this year, with regulatory reviews currently underway in other regions, including the European Union and Switzerland. To view Multimedia News Release, go to

Comments have been deactivated for this video.